IFNB1 and myeloid sarcoma: Given that the treatment effect of some MS therapies, such as interferon-beta, is partially mediated by improvements in BBB function [36], it is quite possible that the measurement of ΔT1 in this study revealed less BBB breakdown as a function of immunomodulatory therapy.